PTSD awareness day and earnings update

Tonix recently held a post-traumatic stress disorder (PTSD) awareness day to highlight the current standards of care, the unmet medical need of the disease as well as the development plan for TNX-102 SL to treat it. The first Phase III trial in military-related PTSD will enroll up to 550 patients and will have one to two interim analyses, which would allow for early stoppage due to efficacy or a sample size adjustment. The trial is expected to start in Q117, with the first interim analyses expected in H217. A second trial in predominantly civilian PTSD is expected to follow.